Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 92
Filter
1.
Sci Rep ; 6: 23500, 2016 Mar 24.
Article in English | MEDLINE | ID: mdl-27009469

ABSTRACT

Somatic mosaicism, the presence of genetically distinct cells within an organism, has been increasingly associated with human morbidity, ranging from being a cause of rare syndromes to a risk factor for common disorders such as malignancy and cardiovascular disease. Previous studies interrogating the normal prevalence of somatic mosaicism have focused on adults. We here present an estimate of the baseline frequency of somatic mosaic copy number variation (CNV) at the time around birth, by sampling eight different organs from a total of five fetuses and newborns. Overall we find a significantly lower frequency of organ specific (i.e. mosaic) CNVs as compared to adults (p = 0.003; Mann-Whitney U-test). The rate of somatic CNV in adults has been estimated to around 2.2 CNV per organ assayed. In contrast, after stringent filtering, we found no organ-private CNVs in fetuses or newborns with exception of the thymus. This organ exhibited a specific genome profile in the form of deletions resulting from polyclonal T-cell receptor rearrangements. This implies that somatic non-immune related CNVs, if present at birth, are typically confined to very small cell populations within organs.


Subject(s)
DNA Copy Number Variations , Gene Rearrangement, T-Lymphocyte , Genes, T-Cell Receptor , Thymus Gland/embryology , Genome, Human , Humans , Infant, Newborn , Male , Mosaicism , Organ Specificity
2.
Amino Acids ; 36(2): 273-82, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18368465

ABSTRACT

Polyamines are important for cell growth and proliferation and they are formed from arginine and ornithine via arginase and ornithine decarboxylase (ODC). Arginine may alternatively be metabolised to NO via NO synthase. Here we study if vascular smooth muscle cell proliferation can be reversed by polyamine synthesis inhibitors and investigate their mechanism of action. Cell proliferation was assessed in cultured vascular smooth muscle A7r5 cells and in endothelium-denuded rat arterial rings by measuring [3H]-thymidine incorporation and by cell counting. Cell cycle phase distribution was determined by flow cytometry and polyamines by HPLC. Protein expression was determined by Western blotting. The ODC inhibitor DFMO (1-10 mM) reduced polyamine concentration and attenuated proliferation in A7r5 cells and rat tail artery. DFMO accumulated cells in S phase of the cell cycle and reduced cyclin A expression. DFMO had no effect on cell viability and apoptosis as assessed by fluorescence microscopy. Polyamine concentration and cellular proliferation were not affected by the arginase inhibitor NOHA (100-200 microM) and the NO synthase inhibitor L-NAME (100 microM). Lack of effect of NOHA was reflected by absence of arginase expression. Polyamine synthesis inhibition attenuates vascular smooth muscle cell proliferation by reducing DNA synthesis and accumulation of cells in S phase, and may be a useful approach to prevent vascular smooth muscle cell proliferation in cardiovascular diseases.


Subject(s)
Muscle, Smooth, Vascular/cytology , Polyamines/antagonists & inhibitors , S Phase , Animals , Apoptosis/drug effects , Apoptosis/physiology , Cell Cycle/drug effects , Cell Line , Cell Proliferation/drug effects , Cell Survival/drug effects , Cell Survival/physiology , Cyclin A/drug effects , Cyclin A/metabolism , Enzyme Inhibitors/pharmacology , Female , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Ornithine Decarboxylase/metabolism , Ornithine Decarboxylase Inhibitors , Polyamines/metabolism , Rats , Rats, Sprague-Dawley , S Phase/drug effects
3.
Int J Gynecol Cancer ; 14(3): 437-50, 2004.
Article in English | MEDLINE | ID: mdl-15228416

ABSTRACT

A management program for FIGO stage I-II nonserous, nonclear-cell adenocarcinomas was evaluated. Histopathology and DNA ploidy were used to estimate postoperatively the risk of progression or death of disease and to tailor treatment. The patient material was a population-based consecutive cohort of all women with endometrial cancer in the Southern Swedish Health Care Region diagnosed between June 1993 and June 1996 (n = 553). Of these, 335 were eligible for the management program. Patients estimated to be at low risk were treated by surgery only, while high-risk patients also received vaginal brachytherapy. A large low-risk group consisting of 84% (n = 283) of the patients with an estimated disease-specific 5-year survival of 96% (95% CI = 93-98%) was identified. The high-risk group (n = 52, 16%) showed a worse outcome with an 80% 5-year disease-specific survival (95% CI = 65-89%). The difference in survival between the groups was highly significant (P < 0.0001). Half of the progressions were distant in the high-risk group. Although there is a clear indication for adjuvant therapy for this group, locoregional radiotherapy could be expected to fail in cases with distant progression. Thus, effective systemic treatments need to be developed. Low-risk patients, constituting the majority (84%) of the patients, can be safely treated by surgery only.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/surgery , Adenocarcinoma/genetics , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/radiotherapy , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Disease Progression , Disease-Free Survival , Endometrial Neoplasms/genetics , Endometrial Neoplasms/mortality , Endometrial Neoplasms/pathology , Endometrial Neoplasms/radiotherapy , Female , Humans , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Ploidies , Prospective Studies , Radiotherapy, Adjuvant , Registries , Risk Factors , Survival Analysis , Sweden/epidemiology
4.
Leukemia ; 18(3): 538-47, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14712293

ABSTRACT

Chronic myeloid leukemia (CML) is characterized by the expression of the P210 BCR/ABL fusion protein. The molecular mechanisms behind this oncogene-mediated hematological disease are, however, not fully understood. Here, we describe the establishment and phenotypic characterization of U937 cells in which P210 BCR/ABL can be conditionally expressed using tetracycline. The induction of BCR/ABL in the obtained clones resulted in a rapid phosphorylation of the STAT1, STAT3 and STAT5 molecules, consistent with the findings in other model systems. Phenotypic characterization of the clones revealed that BCR/ABL induces a slight decrease in the proliferation and viability, without a marked effect on cell cycle distribution, the rate of apoptosis or on cellular differentiation, as judged by several cell surface markers and capacity to reduce nitro blue tetrazolium. Interestingly, BCR/ABL was found to upregulate the expression of carcinoembryonic-related antigen (CEA)CAM1 (CD66a), which is a plasma membrane-linked glycoprotein belonging to the CEAs and involved in signal transduction and cellular adhesion. The expression of CEACAM1 was reversible upon imatinib treatment in BCR/ABL-expressing U937 cells as well as in BCR/ABL-positive K562 cells. The established cell lines may prove useful in further modeling and dissection of BCR/ABL-induced leukemogenesis.


Subject(s)
Antigens, CD/metabolism , Antigens, Differentiation/metabolism , Fusion Proteins, bcr-abl/genetics , Leukemia/metabolism , Milk Proteins , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Benzamides , Carcinoembryonic Antigen/metabolism , Cell Adhesion Molecules , Cell Cycle/drug effects , Cell Differentiation/drug effects , DNA-Binding Proteins/metabolism , Fusion Proteins, bcr-abl/metabolism , Humans , Imatinib Mesylate , K562 Cells , Leukemia/pathology , Phenotype , Piperazines/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Pyrimidines/pharmacology , STAT1 Transcription Factor , STAT3 Transcription Factor , STAT5 Transcription Factor , Trans-Activators/metabolism , Transfection , U937 Cells , Up-Regulation
5.
BMC Cancer ; 3: 11, 2003 Apr 09.
Article in English | MEDLINE | ID: mdl-12697074

ABSTRACT

BACKGROUND: Patients with possible radiation induced cancer could be used to study if the rate of tumour cell proliferation is related to latency time. Such a finding could help researcher to find time periods when other initiating risk factors operate. METHODS: Seventeen women with breast cancer, with a prior history of radiation treatment towards the parts or the whole breast, exclusive of the primary treatment of a breast cancer were identified. Most women had received treatment for benign disorders as hemangiomas, shoulder pain or skin infections. Three patients had been treated with mantle radiation for Hodgkin's disease prior to developing breast cancer. DNA analysis were performed, on remaining tumour tissue after hormone receptor analysis had been done, measuring the fraction of tumour cells in S-phase. Latency time (time between diagnosis and previous radiation treatment) was calculated and related to the S-phase fraction. RESULTS: A significant inverse relationship between latency time and S-phase was found (p < 0.0025), indicating that tumours with a high S-phase had a short latency time and vice versa. Among the possible radiation induced tumours, median S-phase was 14%, comparable with a median latency time of 22 years. Very high S-phase values were associated with short latency times (eg a S-phase of 35% would be compatible with a latency time of 7 years). CONCLUSION: Our preliminary results indicate that S-phase is related to latency time and that the median latency time maybe as long as 22 years. Our data may also explain why breast cancer is rare before 30 years of age and if patients are diagnosed at early ages, tumours often show high S-phase values and bad prognostic signs. We postulate that these results from radiation induced breast cancer may be used to extrapolate possible latency times in patients with non radiation induced breast tumours in order to isolate possible time periods for research after other initiating events.


Subject(s)
Breast Neoplasms/etiology , Neoplasms, Radiation-Induced/etiology , Adult , Aged , Breast Neoplasms/pathology , Cell Division , Female , Humans , Middle Aged , Neoplasms, Radiation-Induced/pathology , Radiation, Ionizing , S Phase , Time Factors
6.
Cytometry ; 46(3): 121-35, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11449403

ABSTRACT

Developing a reliable and quantitative assessment of the potential virulence of a malignancy has been a long-standing goal in clinical cytometry. DNA histogram analysis provides valuable information on the cycling activity of a tumor population through S-phase estimates; it also identifies nondiploid populations, a possible indicator of genetic instability and subsequent predisposition to metastasis. Because of conflicting studies in the literature, the clinical relevance of both of these potential prognostic markers has been questioned for the management of breast cancer patients. The purposes of this study are to present a set of 10 adjustments derived from a single large study that optimizes the prognostic strength of both DNA ploidy and S-phase and to test the validity of this approach on two other large multicenter studies. Ten adjustments to both DNA ploidy and S-phase were developed from a single node-negative breast cancer database from Baylor College (n = 961 cases). Seven of the adjustments were used to reclassify histograms into low-risk and high-risk ploidy patterns based on aneuploid fraction and DNA index optimum thresholds resulting in prognostic P values changing from little (P < 0.02) or no significance to P < 0.000005. Other databases from Sweden (n = 210 cases) and France (n = 220 cases) demonstrated similar improvement of DNA ploidy prognostic significance, P < 0.02 to P < 0.0009 and P < 0.12 to P < 0.002, respectively. Three other adjustments were applied to diploid and aneuploid S-phases. These adjustments eliminated a spurious correlation between DNA ploidy and S-phase and enabled them to combine independently into a powerful prognostic model capable of stratifying patients into low, intermediate, and high-risk groups (P < 0.000005). When the Baylor prognostic model was applied to the Sweden and French databases, similar significant patient stratifications were observed (P < 0.0003 and P < 0.00001, respectively). The successful transference of the Baylor prognostic model to other studies suggests that the proposed adjustments may play an important role in standardizing this test and provide valuable prognostic information to those involved in the management of breast cancer patients.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/metabolism , Flow Cytometry/methods , Lymphatic Metastasis , Ploidies , S Phase , DNA/metabolism , Databases, Factual , Humans , Models, Statistical , Prognosis , Time Factors
7.
Hum Pathol ; 32(3): 311-9, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11274641

ABSTRACT

Simultaneous overexpression of c-erbB-2 and p53 has been reported to be prognostically unfavorable in breast cancer. Herein, we show that concurrent overexpression of these 2 proteins is associated with a marked reduction in the relative fraction of cells in G(1) phase of the cell cycle, indicating an accelerated cell cycle progression. Using an immunohistochemical approach, we examined 261 cases of node-negative infiltrating ductal carcinomas of the breast with respect to c-erbB-2 and p53 expression and to the proliferative activity measured by the Ki-67 index. By means of a novel monoclonal antibody, Ki-S2, which exclusively recognizes proliferating cells in the S, G(2), and M phases of the reproductive cycle, we were further able to calculate the relative fraction of the cells having passed the restriction point at the G(1)/S boundary, thus defining a cycling ratio (CR). The results were correlated with clinical outcome; median follow-up time was 96 months. Tumors that simultaneously overexpressed c-erbB-2 and p53 had a high median CR and followed an unfavorable course. However, increased CRs were also observed independently of c-erbB-2 and p53 overexpression, suggesting that other molecular mechanisms may contribute to acceleration of cell cycle progression. In a multivariate analysis that included patient age, tumor size, hormone receptor status, c-erbB-2 and p53 expression, and the Ki-67 index, CR emerged as the most significant independent predictor of overall and disease-free survival (P <.0001). It is concluded that the CR is a gauge of cell cycle deregulation and therefore may be a powerful indicator of the biologic behavior of cancers. HUM PATHOL 32:311-319.


Subject(s)
Breast Neoplasms/chemistry , Breast Neoplasms/pathology , Cell Cycle , Lymph Nodes/pathology , Receptor, ErbB-2/analysis , Tumor Suppressor Protein p53/analysis , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carcinoma, Ductal, Breast/chemistry , Carcinoma, Ductal, Breast/pathology , Cell Division , Female , G1 Phase , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Middle Aged , Prognosis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis
8.
Cancer Res ; 61(3): 1214-9, 2001 Feb 01.
Article in English | MEDLINE | ID: mdl-11221853

ABSTRACT

Breast carcinoma is thought to arise because of multiple successive changes in the genome of the normal epithelial cells. However, little is known of the order of appearance of different types of genetic aberrations We studied the ERBB2 (Her-2/neu) and CCND1 (cyclin D1) oncogene amplification in flow cytometrically sorted diploid and nondiploid tumor cell populations by fluorescence in situ hybridization (FISH). The purity of the cell sorting was confirmed by static DNA image cytometry. Spectral karyotyping was used to define differences in a genome-wide manner between two distinctly different aneuploid cell clones found in each of two breast cancer cell lines. FISH indicated the presence of gene amplification both in diploid and nondiploid cell clones in 17 of the 21 amplification-containing tumors analyzed. The oncogene copy numbers remained unchanged throughout aneuploidization in 11 of 17 tumors. The remaining six tumors showed an increase in oncogene copy number as well as the number of chromosome 11 or 17 centromeres (the original location of CCNDI and ERBB2, respectively). Breast carcinoma cell lines MDA-157 and MDA-436 showed a significant number of chromosomal rearrangements in the near-diploid clones, which were present in duplicate in the corresponding aneuploid (polyploid) clones. These results indicate that ploidy shift, ie., aneuploidization, in breast cancer is a late genetic event which is preceded by both oncogene amplifications as well as many chromosomal rearrangements.


Subject(s)
Aneuploidy , Breast Neoplasms/genetics , Gene Amplification , Gene Rearrangement , Chromosome Aberrations , Cyclin D1/genetics , Diploidy , Flow Cytometry , Gene Dosage , Genes, erbB-2 , Humans , In Situ Hybridization, Fluorescence , Karyotyping
9.
Clin Lab Med ; 21(4): 875-95, x, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11770293

ABSTRACT

Both DNA ploidy and S-phase ploidy are promising prognostic factors for node-negative breast cancer patients. Based largely on the analysis of one large study, much of the reported problems with these factors have been caused by some unappreciated complexities in categorizing DNA ploidy into low- and high-risk groups and the lack of some necessary adjustments to eliminate unwanted correlations between DNA S-phase and ploidy. When both DNA ploidy and S-phase are compensated properly, they become independent prognostic markers, forming a powerful prognostic model.


Subject(s)
Breast Neoplasms/pathology , Cell Cycle/physiology , DNA, Neoplasm/analysis , Flow Cytometry/methods , Breast Neoplasms/genetics , Breast Neoplasms/mortality , Disease-Free Survival , Female , France/epidemiology , Humans , Ploidies , Prognosis , Sweden/epidemiology
10.
Breast Cancer Res Treat ; 60(3): 219-26, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10930109

ABSTRACT

In a consecutive and unselected series of 178 cases of carcinoma in situ of the breast (CIS), comprising both ductal (DCIS) and lobular type (LCIS), and a series of 48 cases of invasive carcinoma (IC) with predominance of DCIS, the association between histopathology, immunohistochemical markers (ER, PgR, MIB-1, c-erbB-2, and p53), and DNA ploidy was investigated, in order to discriminate biologically different groups. In DCIS, significant correlation was shown between large nuclear size and comedonecrosis, both of which showed also strong association to DNA aneuploidy, high proliferation activity, low steroid receptor content, and overexpression of c-erbB-2 and p53 factors that may indicate an aggressive behavior. Small nuclear CIS, whether LCIS or DCIS, on the contrary, were DNA diploid with low proliferation, and no cases showed overexpression of c-erbB-2 and p53. Heterogeneity with respect to the investigated parameters was also a frequent finding that may reflect a development complexity. In IC, comparison of the DCIS and the invasive component showed similar patterns. No significant differences were shown between DCIS without and with invasion. This may indicate that none of the investigated parameters on its own are essential for the event of invasion.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/pathology , Carcinoma in Situ/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , DNA, Neoplasm/analysis , Neoplasm Proteins/metabolism , Ploidies , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Carcinoma in Situ/genetics , Carcinoma in Situ/metabolism , Carcinoma, Ductal, Breast/genetics , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Lobular/genetics , Carcinoma, Lobular/metabolism , Female , Genetic Markers , Humans , Immunohistochemistry , Mastectomy , Necrosis , Neoplasm Invasiveness
11.
Breast Cancer Res Treat ; 59(1): 69-76, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10752681

ABSTRACT

A Swedish cooperative trial demonstrated that 5 years of adjuvant tamoxifen was more beneficial than 2 years of tamoxifen in the treatment of postmenopausal women with estrogen receptor (ER) positive, early stage, invasive breast cancer. The main aim of the present study was to investigate the importance of progesterone receptor (PgR) and ER concentration levels for patients participating in the trial and still distant recurrence free two years after the primary operation. Subgroup analyses revealed that only patients with ER positive and PgR positive breast cancer had improved distant recurrence free survival (DRFS) by prolonged tamoxifen therapy (p = 0.0016). Patients with ER negative and PgR negative as well as ER positive and PgR negative tumors showed no significant effect of prolonged tamoxifen (p = 0.53 and p = 0.80, respectively). The percentage of ER negative and PgR positive breast cancers was too small (2.2%) for any meaningful subgroup analysis. There was a significant positive trend that the concentration level of PgR (high positive vs. low positive vs. negative) decreased the recurrence rate for those with prolonged therapy. No corresponding pattern was found for the ER content. S-phase fraction did not correlate to the recurrence rate of PgR positive breast cancers. Patients recurring during tamoxifen therapy had receptor negative tumors to a greater extent than those recurring after tamoxifen treatment. In conclusion, prolonged tamoxifen therapy for 5 years instead of 2 years was found to be beneficial for patients with ER positive and PgR positive breast cancer, whereas three extra years of tamoxifen had little or no effect for patients with ER positive but PgR negative tumors as well as for steroid receptor negative patients.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Tamoxifen/therapeutic use , Adult , Aged , Antineoplastic Agents, Hormonal/administration & dosage , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Disease Progression , Female , Humans , Middle Aged , Neoplasm Recurrence, Local , Predictive Value of Tests , Prognosis , Tamoxifen/administration & dosage , Time Factors , Treatment Outcome
12.
Cancer Genet Cytogenet ; 118(1): 42-7, 2000 Apr 01.
Article in English | MEDLINE | ID: mdl-10731589

ABSTRACT

Two synchronous bilateral breast carcinomas and their matched lymph node metastases from a 70-year-old man were cytogenetically analyzed. All four tumors were near-diploid, and except for the primary tumor from the right breast, had a 45,X,-Y clone in common. The loss of the Y chromosome was, however, common to all four tumors, whereas metaphase cells from peripheral blood lymphocytes showed a normal 46, XY chromosome complement. The primary tumor from the right breast was monoclonal, with loss of the Y chromosome and gain of 1q, whereas its metastasis had two related clones: the 45,X,-Y clone, and the other a more complex version of the clone in the primary tumor, with inv(3), -14, and del(16)(q13) as additional changes. The primary tumor from the left breast was polyclonal with three unrelated clones: 45,X,-Y/45,XY,-18/47,XY,+20, two of which were present in its metastasis. DNA flow cytometric studies showed diploidy for both primary tumors. No mutation in the BRCA2 gene was found on analysis of DNA from peripheral blood lymphocytes. The present findings show that del(16)(q13) is a recurrent finding among male breast carcinomas and that some of the primary cytogenetic abnormalities, as well as the pattern of chromosomal changes during the progression of sporadic breast carcinoma in the male, are similar to those in the female. In addition, the loss of the Y chromosome in the tumors but not in peripheral blood lymphocytes, suggests a possible role for this abnormality in the pathogenesis of male breast carcinoma.


Subject(s)
Breast Neoplasms, Male/genetics , Breast Neoplasms, Male/pathology , Chromosome Aberrations/genetics , Lymphatic Metastasis/genetics , Neoplasm Proteins/genetics , Transcription Factors/genetics , Aged , Aneuploidy , BRCA2 Protein , Carcinoma, Ductal, Breast/genetics , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/secondary , Chromosome Deletion , Clone Cells/metabolism , Clone Cells/pathology , Flow Cytometry , Genetic Predisposition to Disease/genetics , Germ-Line Mutation/genetics , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Lymphatic Metastasis/pathology , Lymphocytes/metabolism , Male , Receptors, Estrogen/analysis , Y Chromosome/genetics
13.
J Pathol ; 187(2): 207-16, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10365096

ABSTRACT

Various new prognostic indicators have been identified for mammary carcinomas, but the issue of their significance remains unsettled. The prognostic impact of p53, c-erbB-2, and topoisomerase II alpha expression was investigated in relation to standard prognostic factors for carcinomas of the breast and to the tumour cell growth fraction. Paraffin-embedded specimens of 356 node-negative infiltrating ductal carcinomas were stained immunohistochemically using a polyclonal antiserum to c-erbB-2, and the monoclonal antibodies DO-1 (p53), Ki-S4 (topoisomerase II alpha), and Ki-S5 (Ki-67). The patients were followed for a median duration of 99 months. Both p53 and c-erbB-2 were significantly associated with high tumour grade, large tumour size, DNA aneuploidy, lack of steroid hormone receptors, young age, and increased topoisomerase II alpha and Ki-67 expression levels. The correlation of p53 and c-erbB-2 was not significant. Topoisomerase II alpha and Ki-67 scores closely paralleled each other, indicating that both reflect the proliferative activity of tumour cells. A univariate analysis of overall (OS), specific (SS), and disease-free survival (DFS) revealed all the above-mentioned parameters to be statistically significant except patient age, which was relevant only to overall survival. Multivariate analysis with inclusion of all covariates selected tumour size and proliferation (topoisomerase II alpha and Ki-67) indices as independent predictors of survival in all three models. No additional information was gained by p53 or c-erbB-2. It is concluded that the proliferative activity, as assessed by topoisomerase II alpha or Ki-67 immunostaining, is the most useful indicator of breast cancer prognosis, except for tumour size.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , DNA Topoisomerases, Type II , Neoplasm Proteins/metabolism , Ploidies , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Division , DNA Topoisomerases, Type II/metabolism , DNA-Binding Proteins , Female , Follow-Up Studies , Humans , Isoenzymes/metabolism , Ki-67 Antigen/metabolism , Middle Aged , Prognosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Survival Rate , Tumor Suppressor Protein p53/metabolism
14.
Genes Chromosomes Cancer ; 25(2): 115-22, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10337995

ABSTRACT

The analysis of chromosomal imbalances in solid tumors using comparative genetic hybridization (CGH) has gained much attention. A survey of the literature suggests that CGH is more sensitive in detecting copy number aberrations than is karyotyping, although careful comparisons between CGH and cytogenetics have not been performed. Here, we compared cytogenetics and CGH in 29 invasive breast cancers after converting the karyotypes into net copy number gains and losses. We found 15 tumors (56%) with a significant agreement between the two methods and 12 tumors (44%) where the methods were in disagreement (two cases failed CGH analysis). Interestingly, in 13 of the 15 tumors where the two methods were concordant, there was also a strong correlation between chromosome index and DNA index by flow cytometry. In the opposite situation, i.e., when chromosome and DNA indices were not matching, there was disagreement between cytogenetics and CGH in 10 of the 12 tumors. Of the discordant cases, all except one had a "simple" abnormal karyotype. Unresolved chromosomal aberrations (marker chromosomes, homogeneously staining regions, double minutes) could not completely explain the differences between CGH and karyotyping. A likely explanation for the discrepancies is that the methods analyzed different cell populations. Gains and losses found by CGH represented the predominant (often aneuploid) clone, whereas the abnormal, near-diploid karyotypes represented minor cell clone(s), which, for unknown reasons, had a growth advantage in vitro.


Subject(s)
Chromosome Aberrations/genetics , Cytogenetics/methods , Nucleic Acid Hybridization/methods , Aneuploidy , Breast Neoplasms , Chromosome Mapping , Humans , Karyotyping , Ploidies
15.
Br J Cancer ; 79(7-8): 1205-9, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10098760

ABSTRACT

The S-phase fraction (SPF) in flow cytometric DNA histograms in soft tissue sarcoma (STS) can be calculated in various ways. The traditional planimetric method of Baisch has been shown to be prognostic, but is hampered by a failure rate of around 40%. We therefore tested other models to see if this rate could be decreased with retained prognostic value. In 259 STS of the locomotor system the SPF was calculated according to Baisch and with commercial parametric MultiCycle software using different corrections for background. Using the Baisch model, 159 histograms could be evaluated for SPF. The 5-year metastasis-free survival rate (MFSR) was 0.94 for the low-risk group (defined with SPF), and 0.53 for the high-risk group. In the low-risk group, four of the seven patients who developed metastasis did so after 5 years Using the MultiCycle software, SPF could be calculated in 253 tumours. Depending on type of background correction used, the 5-year MFSR varied between 0.67 and 0.82 for the low-risk group, and between 0.47 and 0.53 for the high-risk group. The late metastasis pattern in the low-risk group was never seen using the MultiCycle software. We conclude that in paraffin archival material, calculation of SPF according to Baisch is preferable in clinical use due to better separation between low-risk and high-risk groups, and also the possibility to identify patients who metastasize late.


Subject(s)
S Phase/genetics , Sarcoma/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Flow Cytometry , Humans , Male , Middle Aged , Prognosis , Sarcoma/mortality
16.
J Natl Cancer Inst ; 91(3): 271-8, 1999 Feb 03.
Article in English | MEDLINE | ID: mdl-10037106

ABSTRACT

BACKGROUND: Proper treatment of lymph node-negative breast cancer depends on an accurate prognosis. To improve prognostic models for this disease, we evaluated whether an immunohistochemical marker for proliferating cells, Ki-S2 (a monoclonal antibody that binds to a 100-kd nuclear protein expressed in S, G2, and M phases of the cell cycle), is an accurate indicator of prognosis. METHODS: We studied 371 Swedish women with lymph node-negative breast cancer; the median follow-up time was 95 months. The fraction of tumor cells in S phase was assessed by flow cytometry, and tumor cell proliferation was measured immunohistochemically with the monoclonal antibodies Ki-S2 and Ki-S5 (directed against the nuclear antigen Ki-67). A combined prognostic index was calculated on the basis of the S-phase fraction, progesterone receptor content, and tumor size. RESULTS: In multivariate analyses that did or did not (263 and 332 observations, respectively) include the S-phase fraction and the combined prognostic index, the Ki-S2 labeling index (percentage of antibody-stained tumor cell nuclei) emerged as the most statistically significant predictor of overall survival, disease-specific survival, and disease-free survival (all two-sided P<.0001). In the risk group defined by a Ki-S2 labeling index of 10% or less, life expectancy was not statistically significantly different from that of age-matched women without breast cancer, whereas the group with a high Ki-S2 labeling index had an increased risk of mortality of up to 20-fold. CONCLUSIONS: Cellular proliferation is a major determinant of the biologic behavior of breast cancer. Prognosis is apparently best indicated by the percentage of cells in S through M phases of the cell cycle. Measurement of the Ki-S2 labeling index of a tumor sample may improve a clinician's ability to make an accurate prognosis and to identify patients with a low risk of recurrence who may not need adjuvant therapy.


Subject(s)
Antibodies, Monoclonal/blood , Antigens, Neoplasm/immunology , Biomarkers, Tumor/blood , Breast Neoplasms/immunology , Ki-67 Antigen/immunology , S Phase/immunology , Adult , Aged , Aged, 80 and over , Analysis of Variance , Breast Neoplasms/pathology , Disease-Free Survival , Female , Flow Cytometry , Humans , Immunohistochemistry , Lymphatic Metastasis , Middle Aged , Predictive Value of Tests , Prognosis , Survival Analysis , Sweden
17.
Anal Cell Pathol ; 19(2): 91-8, 1999.
Article in English | MEDLINE | ID: mdl-10746439

ABSTRACT

Energy transfer in flow cytometry can occur when two fluorochromes are bound in close proximity (generally within 100 A) and the emission spectrum of one fluorochrome overlaps significantly with the excitation spectrum of the other. The latter criterium is fulfilled for the fluorochromes fluorescein isothiocyanate and propidium iodide and also the former when they, e.g., are used in bromodeoxyuridine - DNA flow cytometry methods. In the present growth kinetic study using this method, we show that energy transfer does take place between fluorescein isothiocyanate and propidium iodide which results in a detected increase in DNA content with 2-3%. Despite the erroneous increase in the obtained DNA content values, this does not seem to have any influence on the calculation of DNA synthesis time and potential doubling time where the DNA content, based on the relative movement principle of the labelled cells, is used.


Subject(s)
Adenocarcinoma/pathology , Breast Neoplasms/pathology , Coloring Agents/chemistry , Flow Cytometry/methods , Fluorescein-5-isothiocyanate/chemistry , Fluorescent Dyes/chemistry , Propidium/chemistry , Adenocarcinoma/chemistry , Adenocarcinoma/genetics , Animals , Antibodies, Monoclonal , Antimetabolites/analysis , Antimetabolites/immunology , Breast Neoplasms/chemistry , Breast Neoplasms/genetics , Bromodeoxyuridine/analysis , Bromodeoxyuridine/immunology , CHO Cells , Cricetinae , DNA, Neoplasm/analysis , DNA, Neoplasm/biosynthesis , Energy Transfer , Female , G1 Phase , G2 Phase , Humans
18.
Cytometry ; 33(4): 385-93, 1998 Dec 01.
Article in English | MEDLINE | ID: mdl-9845432

ABSTRACT

S-phase fraction (SPF), estimated in the flow cytometric DNA histogram, is a prognostic factor in breast cancer. There are, however, some inherent difficulties in the estimation of SPF, such as the influence of debris, aggregates, and normal cells. Most of the available SPF calculation principles try to consider these difficulties, but so far no consensus has been reached with regard to which principle is to be recommended. The aim of the present study was to investigate the prognostic impact of SPF when estimated with different calculation methods in frozen breast cancer samples from 350 patients. Two nonparametric (Rman, Rmin/both rectangle) and three parametric (ACAS/DNA-base, ModFit, and MultiCycle) calculation methods, with and without correction for debris and aggregates, were used. The mean values for SPF varied from 4.3% (ACAS/DNA-base with correction for debris and aggregates) to 9.4% (MultiCycle without any correction for background). The pairwise correlation between methods varied considerably (R = 0.72-0.98). After categorization of SPF values into low SPF (lower two tertiles) and high SPF (upper tertile), all methods yielded statistically significant Pvalues for recurrence-free survival (median follow-up time 67 months), both univariately (0.0004-< 0.0001) and multivariately (0.048-0.0004), after adjusting for nodal status, tumor size, and estrogen receptor status. SPF with background correction did not yield lower P values than SPF without. Regardless of which method was used, SPF showed similar correlations with lymph node involvement, tumor size, and estrogen receptor content. In conclusion, as the mean value of SPF for different calculation methods varies, each laboratory must be restricted to use only one method. Background correction does not seem to improve the prognostic impact of SPF in DNA histograms. Based on the experiences obtained in the present study, S-phase calculation methods without background correction may therefore be the most suitable for routine evaluation of DNA histograms of fresh frozen breast cancer material (ModFit, MultiCycle, and Rman [the latter only for experienced operators]). The nonparametric Rmin, with an automatic setting of the region used for SPF calculation, may be an alternative, but suffers from the disadvantage of not being commercially available yet.


Subject(s)
Breast Neoplasms/genetics , DNA, Neoplasm/analysis , Flow Cytometry/methods , Breast Neoplasms/physiopathology , Female , Humans , Multivariate Analysis , Prognosis , Recurrence , S Phase
19.
Cytometry ; 33(4): 487-91, 1998 Dec 01.
Article in English | MEDLINE | ID: mdl-9845445

ABSTRACT

Measurement of S-phase fraction by DNA flow cytometry is widely used in the analysis of human tumors. The calculation of fraction of S-phase cells is performed either by means of curve-fitting techniques or by more simple planimetric methods. Estimates by the latter often suffer from subjectivity or poor adaptation to complex DNA histograms. We describe a variant which is based on the rectangular model. The height of the rectangle is automatically determined from the lowest density value in the S-phase interval. The variant was tested on 141 DNA histograms, and the results were compared with those obtained with other variants based on the rectangular model. The new variant is thought to circumvent some of the problems concerning subjectivity and disturbances caused by aggregate peaks.


Subject(s)
Breast Neoplasms/genetics , DNA, Neoplasm/analysis , Flow Cytometry/methods , Female , Humans , S Phase
20.
Exp Hematol ; 26(11): 1043-52, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9766444

ABSTRACT

Observations based on overexpression of the suppressor gene p53 or interference with endogenous p53 support a role for p53 in mediating not only growth inhibition and apoptosis but also differentiation. The aim of this study was to characterize the mechanisms of p53-dependent differentiation in the monoblastic leukemia cell line U-937. These cells were transfected with a mutant of the p53 gene expressing wild-type p53 at a permissive temperature. The results showed that wild-type p53 and interferon (IFN)-gamma were able to work synergistically to promote differentiation. This cooperative response was not associated with early G1 arrest of the cell cycle, indicating that p53 can mediate differentiation by mechanisms other than those used for mediating G1 arrest. The differentiation response to transfected p53 with or without INF-gamma was inhibited by cyclic adenosine monophosphate (cAMP)-inducing agents (dibutyryl cyclic adenosine 3':5'-monophosphate, forskolin, and 3-isobutyl-1-methylxanthine) in a dose-dependent manner. In contrast, the differentiation response of p53-negative U-937 cells to 1,25-dihydroxychole-calciferol or all-trans retinoic acid was enhanced by cAMP-inducing agents at optimal concentrations and inhibited at higher concentrations. In addition, 1,25-dihydroxycholecalciferol-mediated differentiation could be achieved in cells arrested in G1 by concomitant incubation with cAMP-inducing agents, indicating that differentiation can occur in the absence of proliferation. In conclusion, the results of this study indicate that p53-dependent and -independent differentiation can occur independently of cell cycle regulation.


Subject(s)
Cell Cycle/genetics , Genes, p53 , Leukemia, Monocytic, Acute/genetics , 1-Methyl-3-isobutylxanthine/pharmacology , Antineoplastic Agents/pharmacology , Cell Death/drug effects , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cholecalciferol/pharmacology , Colforsin/pharmacology , Cyclic AMP/pharmacology , Growth Inhibitors/pharmacology , Humans , Interferon-gamma/pharmacology , Leukemia, Monocytic, Acute/pathology , Tretinoin/pharmacology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...